Bioequivalence Study Design
Bioequivalence Study Design is the pre-specified methodological framework for a clinical pharmacokinetic study that compares the rate and extent of systemic exposure to an active ingredient from a test and a reference medicinal product, defining the experimental structure, study conditions, and statistical procedures required to determine compliance with regulatory bioequivalence criteria.
945
Publications
34.2K
Citations
3.7K
Authors
1.1K
Institutions
Publications per year
2017–2026
137
Variants
Crossover Study DesignCrossover Study DesignsStudy Design For BioequivalenceStudy Design In Bioequivalence
945
1–5 of 945
3.7K
18
h-index
16
h-index
13
h-index
13
h-index
13
h-index
1–5 of 3.7K
1.1K
Center for Drug Evaluation and Research
Silver Spring, United States
26 h-index
162 publications
15K citations
United States Food and Drug Administration
Silver Spring, United States
20 h-index
130 publications
8.5K citations

University of Toronto
Toronto, Canada
20 h-index
38 publications
1.1K citations
Bristol-Myers Squibb (United States)
New York, United States
18 h-index
55 publications
2.9K citations
Novartis (Switzerland)
Basel, Switzerland
17 h-index
56 publications
1.5K citations
Pfizer (United States)
New York, United States
13 h-index
47 publications
2.2K citations
Zimmer Biomet (Germany)
Berlin, Germany
13 h-index
36 publications
1.3K citations

National and Kapodistrian University of Athens
Athens, Greece
13 h-index
34 publications
1.1K citations
1–8 of 1.1K
42 publications · 2.1K citations
25
h-index
Repository · 59 publications · 1.7K citations
23
h-index
42 publications · 1.3K citations
22
h-index
35 publications · 1.1K citations
20
h-index
36 publications · 699 citations
16
h-index
1–5